NCT05038735
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05038735
Title Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. (EPIK-B5)
Acronym EPIK-B5
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries SVK | ROU | POL | ITA | IRL | HUN | GRC | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BGR | BEL

Facility Status City State Zip Country Details
Novartis Investigative Site Sint-Niklaas Oost Vlaanderen 9100 Belgium Details
Novartis Investigative Site Brussels 1000 Belgium Details
Novartis Investigative Site Brussels 1200 Belgium Details
Novartis Investigative Site Ghent 9000 Belgium Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Liège 4000 Belgium Details
Novartis Investigative Site Plovdiv 4004 Bulgaria Details
Novartis Investigative Site Sofia 1330 Bulgaria Details
Novartis Investigative Site Calgary Alberta T2N 5G2 Canada Details
Novartis Investigative Site Ottawa Ontario K1H 8L6 Canada Details
Novartis Investigative Site Brno 656 53 Czechia Details
Novartis Investigative Site Nový Jičín 741 01 Czechia Details
Novartis Investigative Site Prague 100 34 Czechia Details
Novartis Investigative Site Prague 128 08 Czechia Details
Novartis Investigative Site Prague 140 59 Czechia Details
Novartis Investigative Site Aalborg 9000 Denmark Details
Novartis Investigative Site Helsinki 00029 Finland Details
Novartis Investigative Site Tampere FIN-33521 Finland Details
Novartis Investigative Site Besançon 25030 France Details
Novartis Investigative Site Clermont-Ferrand 63011 France Details
Novartis Investigative Site La Roche-sur-Yon 85925 France Details
Novartis Investigative Site Lyon 69373 France Details
Novartis Investigative Site Marseille 13273 France Details
Novartis Investigative Site Montpellier 34298 France Details
Novartis Investigative Site Paris 75475 France Details
Novartis Investigative Site Paris 75970 France Details
Novartis Investigative Site Valenciennes 59300 France Details
Novartis Investigative Site Cologne North Rhine-Westphalia 50937 Germany Details
Novartis Investigative Site Augsburg 86150 Germany Details
Novartis Investigative Site Berlin 13353 Germany Details
Novartis Investigative Site Essen 45136 Germany Details
Novartis Investigative Site Lübeck 23538 Germany Details
Novartis Investigative Site Athens 115 22 Greece Details
Novartis Investigative Site Pátrai 265 04 Greece Details
Novartis Investigative Site Budapest H 1122 Hungary Details
Novartis Investigative Site Dublin DO4 Ireland Details
Novartis Investigative Site Bari BA 70124 Italy Details
Novartis Investigative Site Bergamo BG 24127 Italy Details
Novartis Investigative Site Bologna BO 40138 Italy Details
Novartis Investigative Site Florence FI 50134 Italy Details
Novartis Investigative Site Genova GE 16132 Italy Details
Novartis Investigative Site Milan MI 20132 Italy Details
Novartis Investigative Site Milan MI 20133 Italy Details
Novartis Investigative Site Milan MI 20141 Italy Details
Novartis Investigative Site Rozzano MI 20089 Italy Details
Novartis Investigative Site Palermo PA 90127 Italy Details
Novartis Investigative Site Padua PD 35128 Italy Details
Novartis Investigative Site Aviano PN 33081 Italy Details
Novartis Investigative Site Roma RM 00168 Italy Details
Novartis Investigative Site Terni TR 05100 Italy Details
Novartis Investigative Site Napoli 80131 Italy Details
Novartis Investigative Site Bydgoszcz 85 796 Poland Details
Novartis Investigative Site Coimbra 3000-075 Portugal Details
Novartis Investigative Site Lisbon 1099-023 Portugal Details
Novartis Investigative Site Lisbon 1400-038 Portugal Details
Novartis Investigative Site Porto 4200-072 Portugal Details
Novartis Investigative Site Floreşti Cluj 407280 Romania Details
Novartis Investigative Site Bratislava 812 50 Slovakia Details
Novartis Investigative Site Bratislava 83310 Slovakia Details
Novartis Investigative Site Košice 041 91 Slovakia Details
Novartis Investigative Site Badajoz Extremadura 06080 Spain Details
Novartis Investigative Site Pozuelo de Alarcón Madrid 28223 Spain Details
Novartis Investigative Site Oviedo Principality of Asturias 33011 Spain Details
Novartis Investigative Site A Coruña 15009 Spain Details
Novartis Investigative Site Barcelona 08036 Spain Details
Novartis Investigative Site Madrid 28040 Spain Details
Novartis Investigative Site Málaga 29011 Spain Details
Novartis Investigative Site Zaragoza 50009 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field